ESSA Pharma Inc. (NASDAQ:EPIX) Receives “Buy” Rating from Dawson James
ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI)‘s stock had its “buy” rating reiterated by equities research analysts at Dawson James in a research note issued to investors on Thursday.
Other analysts have also issued research reports about the stock. Bloom Burton reaffirmed a “buy” rating on shares of ESSA Pharma in a report on Thursday, May 18th. Zacks Investment Research raised shares of ESSA Pharma from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, ValuEngine lowered shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. ESSA Pharma presently has a consensus rating of “Hold” and a consensus target price of $9.00.
Shares of ESSA Pharma (NASDAQ:EPIX) opened at 0.305 on Thursday. The firm’s market cap is $8.87 million. The stock’s 50 day moving average price is $0.48 and its 200-day moving average price is $1.76. ESSA Pharma has a 12 month low of $0.25 and a 12 month high of $3.59.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/08/essa-pharma-inc-nasdaqepix-receives-buy-rating-from-dawson-james.html.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.